For the Inventor, By the Inventor

Enter assignee name

Hong Kong, China

Ascentage Pharma Group Corp Limited

USPTO Granted Patents = 29

EPO Patents = 12

Trademarks = 13

Forward Citations = 8

Loading Chart...

Loading Chart...

60 inventors (with patents filed for the assignee):

Dajun Yang (12 out of 22 patents)

Yifan Zhai (12 out of 22 patents)

Douglas Dong Fang (8 out of 14 patents)

4. Jianfeng Wen (7 out of 9 patents)

5. Yanqiong Lin (6 out of 7 patents)

6. Qiuqiong Tang (5 out of 8 patents)

7. Ming Guo (4 out of 6 patents)

8. Tianzhu Wu (4 out of 6 patents)

9. Huirong Lu (4 out of 4 patents)

10. Jianpeng Feng (4 out of 6 patents)

11. Feng Xu (3 out of 8 patents)

12. Saijie Zhu (3 out of 3 patents)

13. Chao-Yie Yang (3 out of 17 patents)

14. Yunlong Zhou (3 out of 7 patents)

15. Yu Jing (3 out of 7 patents)

Core Competencies:

Bcl-2 Inhibitors

MDM2 Inhibitors

Cancer Treatment

Pharmaceutical Compositions

Systemic Lupus Erythematosus

Sulfonamide Compounds

Macrocyclic Compounds

Tricyclic Compounds

Apoptosis Pathway

Solid Dispersion

Crystalline Forms

Therapeutic Applications

29 patents: Sort by Forward Citations

1. 12746221 - Combinations of Bcl-2/Bcl-xL inhibitors and related uses (2026-09-29),

2. 12728113 - Microsuspension of an MDM2 inhibitor and therapeutic applications thereof (2026-09-08),

3. 12686684 - BTK degrader and use thereof (2026-07-21),

4. 12661324 - Solid dispersion, pharmaceutical preparations, preparation method, and application thereof (2026-06-23),

5. 12648945 - Compositions and methods for treating systemic lupus erythematosus (2026-06-09),

6. 12630553 - Crystalline forms or amorphous forms of bisdiazabicyclic compounds or salts thereof (2026-05-19),

7. 12577245 - Sulfonyl benzamide derivatives as Bcl-2 inhibitors (2026-03-17),

8. 12528832 - Crystalline or amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts (2026-01-20),

9. 12514863 - Pharmaceutical combination and use thereof (2026-01-06),

10. 12370197 - Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases (2025-07-29),

11. 12358912 - Crystalline forms or amorphous forms of N-(phenyl sulfonyl) benzamide compounds or its salts or solvates (2025-07-15),

12. 12343352 - N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors (2025-07-01),

13. 12319703 - Macrocyclic fused pyrazoles as Mcl-1 inhibitors (2025-06-03),

14. 12287338 - Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway (2025-04-29),

15. 12233047 - Pharmaceutical combination and use thereof (2025-02-25),

Company Overview

Ascentage Pharma Group Corp Limited is a biopharmaceutical company based in Hong Kong, specializing in the development of innovative therapies for cancer and age-related diseases. The company focuses on targeted therapies and apoptosis modulation, leveraging its expertise in drug discovery and development to address unmet medical needs. With a commitment to advancing healthcare, Ascentage Pharma is engaged in various stages of clinical development, aiming to bring transformative treatments to patients globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

29 Patents

#119 in Hong Kong

#1,055 in China

#22,570 in the World

Hong Kong, China

Ascentage Pharma Group Corp Limited

Forward Citations = 8

60 inventors:

Dajun Yang (12 out of 22 patents)

Yifan Zhai (12 out of 22 patents)

Douglas Dong Fang (8 out of 14 patents)

4. Jianfeng Wen (7 out of 9 patents)

5. Yanqiong Lin (6 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ascentage Pharma Group Corp Limited. Retrieved from https://idiyas.com/company/ascentage-pharma-group

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…